Any current/future capex/capital investment/strategic investment?

Quick Heal Technologies is currently in an investment phase, focusing on innovation and R&D which is fully expensed through P&L, with no capitalization of R&D costs. The company has identified and started investing in multiple new product initiatives, including Horizon-III products and enhancements in Zero Trust, Data Privacy, threat intelligence platforms, and malware analysis. Investments also include embedding Gen AI interfaces to simplify user experience across products. There is no explicit mention of traditional capital expenditure or strategic investments beyond these technology a

Future growth expectations in sales/revenue/volumes?

Enterprise business has grown from 20% to 43% of total revenue in the last three years, indicating strong growth in that segment (Page 8, 14, 15). Horizon-II products (EDR, XDR, MDR, Zero Touch User Access) are in early adoption but expected to contribute significantly going forward, complementing core Horizon-I product revenue (Pages 14-15). The market opportunity is expanding: serviceable market expected to grow to Rs. 3,000 crores in FY'25, Rs. 3,500 crores in FY'26, and Rs. 4,000 crores in FY'27 due to new product additions and geographic expansion (Page 10). Consumer business showing resi

Future growth expectations in earnings/operating earnings/profits/EPS?

Quick Heal anticipates strong growth driven by expanding enterprise business and new product adoption (Horizon-II and upcoming Horizon-III). Horizon-I currently forms the core revenue (majority), but Horizon-II products (EDR, XDR, MDR, Zero Trust) are gaining momentum and expected to drive future growth akin to earlier consumer-to-enterprise transition. Revenue growth backed by expanding serviceable market (Rs. 3,000 crore in FY25 to Rs. 4,000 crore by FY27) through new solutions and geographic expansion. EBITDA improvement expected over the next 2-3 years as revenue grows disproportionately t

Current/ Expected Orderbook/ Pending Orders?

Vishal Salvi mentioned that the company is comfortable with its current pipeline. The pipeline includes enterprise and government business opportunities. There is ongoing work to increase and improve the pipeline for upcoming quarters. The company expects better conversion rates going forward. Specific details about order book or pending orders were not disclosed. Large deal wins happened during the quarter but details and customer specifics remain undisclosed.

Quick Heal Technologies LtdQ1 FY25IT - Software

Quick Heal Technologies Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹151.55Market Cap: ₹821 CrSector: IT - Software

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Enterprise business has grown from 20% to 43% of total revenue in the last three years, indicating strong growth in that segment (Page 8, 14, 15).
Horizon-II products (EDR, XDR, MDR, Zero Touch User Access) are in early adoption but expected to contribute significantly going forward, complementing core Horizon-I product revenue (Pages 14-15).
The market opportunity is expanding: serviceable market expected to grow to Rs. 3,000 crores in FY'25, Rs. 3,500 crores in FY'26, and Rs. 4,000 crores in FY'27 due to new product additions and geographic expansion (Page 10).
Consumer business showing resilience and growth with multiple initiatives and 63% jump in retail segment in Q1 (Pages 4, 10).
New product launches in Horizon-III and integration of Gen AI expected to enhance growth potential over the next 1.5 years to 3 years (Pages 7, 11).
The company targets profitable growth with a balanced approach to investment and cost management (Pages 12, 14).

Margin guidance

Category 3

Quick Heal anticipates strong growth driven by expanding enterprise business and new product adoption (Horizon-II and upcoming Horizon-III).
Horizon-I currently forms the core revenue (majority), but Horizon-II products (EDR, XDR, MDR, Zero Trust) are gaining momentum and expected to drive future growth akin to earlier consumer-to-enterprise transition.
Revenue growth backed by expanding serviceable market (Rs. 3,000 crore in FY25 to Rs. 4,000 crore by FY27) through new solutions and geographic expansion.
EBITDA improvement expected over the next 2-3 years as revenue grows disproportionately to fixed costs and new products mature.
Commitment to profitable growth maintained; no explicit margin guidance yet, but positive EBITDA trajectory anticipated as Horizon-II and Horizon-III products stabilize.
R&D investments continue but balanced with productivity enhancements to sustain margin expansion.
Large deal wins and strong pipeline provide confidence in revenue and earnings growth momentum.

See what Quick Heal Technologies Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript provided from the earnings call and related presentation for Quick Heal Technologies Limited does not mention any current or future plans for fundraising through debt or equity. Specifically: - No references were made to raising capital via debt or equity in the discussed sections. - The company described itself as "a cash-rich company focused on creating long-term value" (Page 4). - Investments are being made through internal accruals with a focus on profitable growth and efficient expense management. - There was no indication of planned external funding rounds. Therefore, based on the given information, Quick Heal Technologies currently has no announced plans for raising funds through debt or equity.

Order book

Vishal Salvi mentioned that the company is comfortable with its current pipeline.
The pipeline includes enterprise and government business opportunities.
There is ongoing work to increase and improve the pipeline for upcoming quarters.
The company expects better conversion rates going forward.
Specific details about order book or pending orders were not disclosed.
Large deal wins happened during the quarter but details and customer specifics remain undisclosed.

See what Quick Heal Technologies Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Quick Heal Technologies is currently in an investment phase, focusing on innovation and R&D which is fully expensed through P&L, with no capitalization of R&D costs.
The company has identified and started investing in multiple new product initiatives, including Horizon-III products and enhancements in Zero Trust, Data Privacy, threat intelligence platforms, and malware analysis.
Investments also include embedding Gen AI interfaces to simplify user experience across products.
There is no explicit mention of traditional capital expenditure or strategic investments beyond these technology and product development programs.
The approach is to balance investments with profitability, focusing on productivity improvements and cost optimization while scaling new products.
The company continues to invest in sales and marketing to support go-to-market initiatives.
No specific future capex or strategic investment figures or plans outside of ongoing R&D and product development were disclosed.

Track Quick Heal Technologies Ltd — get its next earnings analysis in your feed

How does Quick Heal Technologies Ltd rank vs peers in IT - Software?

Pro feature

ThisQuick Heal Technologies Ltd

Rev 2Mar 3

See where Quick Heal Technologies Ltd sits in IT - SoftwareSee which companies these are, and every other name in the sector.Open rankings

How does Quick Heal Technologies Ltd rank in IT - Software?

Compare Quick Heal Technologies Ltd against every IT - Software company (Q1 FY25) on revenue, margins and earnings-call signals.

View IT - Software leaderboard →

What Quick Heal Technologies Ltd's management said in earlier quarters

Others in IT - Software this season

Delaplex (Q1 FY27)
H2 FY26 total income (quarterly equivalent): ₹340.4 Mn vs ₹328.4 Mn in H2 FY25, a 3.66% YoY increase. Key investor presentation takeaways from Delaplex Ltd's Q1
Softtech Enginee (Q2 FY26)
Standalone: Rs 25.71 Cr (up from Rs 22.93 Cr in Q2 FY 2024-25) — approx. Key investor presentation takeaways from Softtech Engineers Ltd's Q2 FY26 investor pres
Systango Tech (Q2 FY26)
Year-on-Year (YoY) revenue growth for H1-FY26 is 58.0% compared to H1-FY25 revenue of INR 288 million. Key investor presentation takeaways from Systango Technol
3i Infotech Ltd (Q2 FY26)
Q2 FY26 consolidated revenue from operations: ₹174.9 crore, a 2.5% increase quarter-on-quarter (QoQ) but a 2% decrease year-on-year (YoY) from ₹177.6 crore in…

Compare:vs Infosys vs Wipro vs Tech Mahindra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →